| Literature DB >> 25498384 |
D J A Goldsmith1, Z A Massy2, V Brandenburg3.
Abstract
Vitamin D is of paramount importance to skeletal development, integrity and health. Vitamin D homeostatis is typically deranged in a number of chronic conditions, of which chronic kidney disease is one of the most important. The use of vitamin D based therapy to target secondary hyperparathyroidism is now several decades old, and there is a large body of clinical practice, experience, guidelines and research to underpin this. However, there are many unknowns, of significant clinical relevance. Amongst which is what "species" of vitamin D we should be using, in what patient, and, under what conditions. Sadly, there has been a real dearth of randomised controlled trials, and trials with outputs of clinical relevance, which means our clinical practice has not developed and refined adequately ove the last 4 decades. This article will discuss the vexed but critical questions of which vitamin D therapies might suit which kidney patients, and will high-light the many important clinical questions which urgently require answering.Entities:
Keywords: LVH; Vitamin D; hypercalcemia; hyperparathyroidism
Mesh:
Substances:
Year: 2014 PMID: 25498384 DOI: 10.1016/j.semnephrol.2014.10.002
Source DB: PubMed Journal: Semin Nephrol ISSN: 0270-9295 Impact factor: 5.299